InvestorsObserver
×
News Home

Is Intellia Therapeutics Inc (NTLA) Stock a Good Value Thursday?

Thursday, May 13, 2021 11:56 AM | InvestorsObserver Analysts

Mentioned in this article

Is Intellia Therapeutics Inc (NTLA) Stock a Good Value Thursday?

Intellia Therapeutics Inc (NTLA) is near the top in its sector according to InvestorsObserver.

NTLA gets an overall rating of 68. That means it scores higher than 68% of stocks.

Intellia Therapeutics Inc gets a 83 rank in the Healthcare sector. Healthcare is number 9 out of 11 sectors.

Overall Score - 68
NTLA has an Overall Score of 68. Find out what this means to you and get the rest of the rankings on NTLA!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector.

Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score.

The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Intellia Therapeutics Inc Stock Today?

Intellia Therapeutics Inc (NTLA) stock is lower by -3.66% while the S&P 500 has gained 1.18% as of 11:43 AM on Thursday, May 13. NTLA is down -$2.34 from the previous closing price of $64.00 on volume of 612,326 shares. Over the past year the S&P 500 has risen 45.77% while NTLA has gained 291.49%. NTLA lost -$2.46 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Intellia Therapeutics Inc (NTLA) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App